Cantor Fitzgerald Rates BioCryst Pharmaceuticals (BCRX) buy

Cantor Fitzgerald maintains its buy rating on BioCryst Pharmaceuticals with a $29 price target, a 190% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 9:03 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Cantor Fitzgerald rated BioCryst Pharmaceuticals, Inc. ($BCRX) "buy" with a $29 price target on June 30, 2026.

Since the rating, $BCRX is up 9.9% after 1 week, down 7.6% after 1 month and down 22.1% to date (from the $10 close on Jun 30, 2026).

BCRX BioCryst Pharmaceuticals, Inc.

$7.79 +3.87% year to date

Daily close · Oct 16, 2026

Key Points

Cantor Fitzgerald reiterated its buy rating on BioCryst Pharmaceuticals, Inc. (BCRX) with a target price of $29 on June 30, 2026.
Cantor Fitzgerald's $29 price target implies 190% upside from BioCryst Pharmaceuticals, Inc.'s ($BCRX) current $10 share price.
Shares of BioCryst traded at $9.55 on Tuesday, with a market cap of approximately $2.53 billion and a forward P/E ratio of 14.6.
Insider buying activity included purchases by Steven Galson and Machelle Sanders on June 11, 2026.

Get $BCRX trade alerts by text

We text you when insiders, Congress or big funds trade $BCRX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated BioCryst Pharmaceuticals, Inc. alert may contain errors. Disclosures

Cantor Fitzgerald has reiterated its buy rating on BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX), maintaining a price target of $29. This announcement was made on June 30, 2026, by analyst Steven Seedhouse. On that same day, shares of BioCryst traded at $9.55.

Analyst rating track record

Cantor Fitzgerald vs. the S&P 500

YTD return +2.10% hypothetical

All-time return +19.85% S&P 500 +17.02%

vs. S&P 500 +2.83% ahead of the index

Hypothetical returns from Cantor Fitzgerald's disclosed trades, not real profit or advice. How we model this.

BioCryst Pharmaceuticals, Inc. Stock Up 15.2%

On Tuesday, BioCryst Pharmaceuticals' stock traded near $9.55. The company, which operates in the healthcare sector, boasts a market capitalization of about $2.53 billion. It has a forward P/E ratio of 14.6 and a beta of 0.565, indicating lower volatility compared to the broader market. Over the past 52 weeks, the stock has ranged from a low of $6.00 to a high of $10.94. Its 50-day moving average is $8.92, while the 200-day moving average stands at $7.97.

12-month forecast

$BCRX price target

BioCryst Pharmaceuticals, Inc. daily closes and this analyst's $29 target. Not advice.

Recent Earnings

BioCryst Pharmaceuticals reported revenue of $885.7 million, reflecting a growth rate of 7.5%. Despite this, the company has a net margin of -51.7%, indicating it is not currently profitable. Earnings per share stand at -$1.77. Investors can look forward to the next earnings announcement on August 3, 2026.

Insider Buying and Selling at BioCryst Pharmaceuticals, Inc.

There has been notable insider buying activity at BioCryst Pharmaceuticals. On June 11, 2026, several insiders, including Steven Galson and Machelle Sanders, purchased shares. Galson bought 33,540 shares, while Sanders acquired 15,294 shares. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On June 30, 2026, Cantor Fitzgerald maintained its buy rating for BioCryst Pharmaceuticals with a $29 price target. Other analysts have also shown interest in the stock. For instance, Citizens maintained a buy rating with a $28 target on May 7, 2026, and Wedbush set a $21 target on the same day. In total, there are 10 analyst opinions, with a mean target price of $21.30.

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company based in Durham, North Carolina. It focuses on developing and commercializing medicines for rare diseases, including hereditary angioedema (HAE). The company markets ORLADEYO, an oral treatment for HAE, and is working on other therapeutic candidates like Navenibart and BCX17725. Under the leadership of CEO Charles K. Gayer, BioCryst employs 435 people.

Bottom Line

Cantor Fitzgerald's reiterated buy rating reflects continued confidence in BioCryst Pharmaceuticals' prospects. Investors watch these analyst ratings closely for insights into a company's potential. It's important to remember that these ratings are based on backward-looking data and may not reflect current market conditions.